(02) 9926 4726

News and Event

The Sydney 1000 Cancer Study

The Sydney 1000 Cancer Study

The role of inflammation and the immune system in cancer is being increasingly recognized. Two key questions that have not been answered are how the host innate and adaptive immune system responds to treatment, and if there is a predictive signature that could be used to inform treatment decisions.

The Sydney 1000 Cancer Study is the first study to follow 1000 patients throughout their disease and treatment trajectory while at the same time enabling the complete collection and matching of tumour and blood samples with clinical history, treatment outcomes and related changes in patient-reported quality of life. A recognised international innovation of this project is the ability to apply the Mass Cytometer-Time of Flight (CyTOF) technology to different cancers to describe the 40 different cell surface and intracellular signaling markers in a single sample. This is the only such instrument available in Australia, allowing us to identify any potential immune response signatures for the two gastrointestinal cancers, colorectal and pancreatic cancer.

With additional leveraged funding, the collection of genomic and proteomic details will be possible to complement the rich clinical and treatment data.

The first stage of this University-wide initiative, will establish the essential reporting systems and harmonised data collection across sites to support not only the proposed project, but also clinical practice and clinical trials.

Team of Investigators:

  • Dr Kellie Charles
  • Prof Stephen Clarke
  • Dr Connie Diakos
  • A/Prof Nick Pavlakis
  • Prof Alexander Engel
  • A/Prof Jas Samra
  • Prof Anthony Gill
  • A/Prof Andrew Kneebone
  • Prof Barbara Fazekas de St Groth
  • Prof Derek Hart
  • A/Prof Scott Byrne
  • Dr Helen McGuire
  • Prof Madeleine King


Flagship Lead
Prof Baxter
Chief Investors
Prof Clarke Prof Marsh Prof Boyle AProf Gill AProf Molloy
Prof Clarke
Prof Marsh
Prof Boyle
A/Prof Gill
A/Prof Molloy
R. Fellow
Dr Ochnik
Dr Ochnik


Proposal Title: Investigation of novel insulin-like growth factor (IGF)- and sphingosine kinase (SphK)-targeted therapies for ER-negative, therapy-resistant breast cancer.

Post a comment